MedicinePOM

Empagliflozin+ Metformin

Synjardy combines empagliflozin and metformin to improve blood sugar in type 2 diabetes.

Clinical information

Common uses

type 2 diabetes (with diet and exercise)
reducing cardiovascular death with established heart disease
heart failure and chronic kidney disease benefits (empagliflozin)

Common side effects

urinary tract infections
female genital yeast infections
diarrhoea, nausea and vomiting
flatulence and stomach discomfort
headache and weakness

Cautions

boxed warning: metformin-associated lactic acidosis can be fatal
not with severe kidney impairment
ketoacidosis can occur — stop if suspected
serious genital infections including Fournier's gangrene reported

Interactions

topiramate and other carbonic anhydrase inhibitors (lactic acidosis risk)
cimetidine, dolutegravir, ranolazine (raise metformin levels)
excessive alcohol (lactic acidosis risk)
diuretics (volume depletion)
insulin or sulfonylureas (low blood sugar risk)
lithium (levels may fall)

Pregnancy: not recommended in the second and third trimesters

Reference information, not medical advice — always follow your doctor or pharmacist. Source: DailyMed, dailymed.nlm.nih.gov, Synjardy (empagliflozin and metformin hydrochloride) label, setid 0fdd0255-0055-65f3-b2c0-db8fbb87beae (accessed 2026-08-16)

Approved brands & formulations8

Brand name	Dosage form	Strength	Importer	Category
Empagliflozin+ Metformin	Tablet	12.5mg+500mg	—	POM
Empagliflozin+ Metformin	Tablet	5mg+ 500mg	—	POM
Empagliflozin+ Metformin	Tablet	12.5mg+1000mg	—	POM
EMPAZIN M 500	Tablet ( Film coated )	5mg+ 500mg (BP )	Meditime Pvt Ltd	POM
Jardiance Met® 12.5mg/1000mg	Tablet ( Film coated )	12.5mg+1000mg	Prime Care Investment Pvt Ltd	POM
Jardiance Met® 12.5mg/1000mg	Tablet ( Film coated )	12.5mg+1000mg	—	POM
Jardiance Met® 12.5mg+500mg	Tablet ( Film coated )	12.5mg+500mg	—	POM
Jardiance Met® 12.5mg+500mg	Tablet ( Film coated )	12.5mg+500mg	Prime Care Investment Pvt Ltd	POM